Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588413 · ClinicalTrials.gov registry record · Phase 3
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
A Phase 3 study of Multiple Myeloma and Autologous Stem Cell Transplantation, sponsored by Augusta University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 172
- Enrollment target
- 1
- Study location
NCT06588413 is a Phase 3 study of Multiple Myeloma and Autologous Stem Cell Transplantation that is actively recruiting participants, run by Augusta University. The registered enrollment target is 172 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06588413, a Phase 3 study of Multiple Myeloma and Autologous Stem Cell Transplantation, is actively recruiting participants, sponsored by Augusta University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 172 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy. A previous research study found the 10 mg dose of olanzapine (combined with 3 standard medications used routinely to prevent nausea/vomiting) to be effective for patients who received melphalan chemotherapy, but several other studies have shown many patients have a side effect of sleepiness (e.g., sedation) with that dose of the medication. Our study will compare two lower doses of olanzapine (5 mg and 2.5 mg) in combination with the 3 standard medications used to prevent nausea/vomiting in the patients who receive melphalan chemotherapy to determine which dose is effective in preventing nausea and vomiting with the lowest amount of sleepiness side effect.
Conditions Studied
Interventions
- DRUG Olanzapine
Study Locations (1)
Georgia
- Wellstar MCG - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2024-09-17 |
| Est. Completion | 2027-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06588413
The ClinicalTrials.gov registry entry for NCT06588413 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (68% lower). The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Olanzapine is the first listed.
NCT06588413 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06588413 about?
NCT06588413 is a clinical study titled "Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan". Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy. A previous research study found the 10 mg dose of olanzapine (combined with 3 standard medications us...
What is the current status of trial NCT06588413?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 172 participants. The study started on 2024-09-17. Estimated completion is 2027-10.
What conditions does trial NCT06588413 study?
This clinical trial studies the following conditions: Multiple Myeloma, Autologous Stem Cell Transplantation.
What interventions are being tested in trial NCT06588413?
The interventions under investigation include: Olanzapine (DRUG).
Who is sponsoring clinical trial NCT06588413?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588413 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.